HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Impaired remyelination due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE). Here, we have demonstrated the potential of lovastatin, a HMG‐CoA reductase inhibitor, for the restoration of impaired remyelination mediated through enhanced survival and differentiation of OPs in the spinal cord of treated EAE animals. Lovastatin treatment significantly increased the level of myelin lipids in the spinal cord of treated EAE animals, coinciding with the attenuation of disease severity and inflammatory demyelination as compared with untreated EAE animals. The increased expression of myelin proteins and transcription factors associated with differentiating oligodendrocytes along with the increase in number of NG2 + /BrdU − and NG2 + /BrdU + cells, and the expression of proliferating OP‐specific proteins, demonstrated the restoration of remyelination in the spinal cord of lovastatin‐treated EAE animals. Corresponding to this, in vitro studies further corroborated the increased survival and differentiation of OPs in lovastatin‐treated activated mixed glial cells suggesting that lovastatin protects against the degeneration of OPs and enhances their differentiation through induction of a pro‐remyelinating environment in the spinal cord of treated EAE animals. Together, these data demonstrate that lovastatin has the potential to augment remyelination in MS lesions and other neuroinflammatory diseases. Paintlia, A. S., Paintlia, M. K., Khan, M., Vollmer, T., Singh, A. K., Singh, I. HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 19, 1407–1421 (2005)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sox10, a Novel Transcriptional Modulator in Glial Cells
Kuhlbrodt, K., Herbarth, B., Sock, E., Hermans-Borgmeyer, I., & Wegner, M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00237.1998 · Cited by 781
Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02451.2002 · Cited by 625
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Endogenous progenitors remyelinate demyelinated axons in the adult CNS
Gensert, J. M., & Goldman, J. E. (1997) · Neuron · doi:10.1016/s0896-6273(00)80359-1 · Cited by 544 · cited 1×
“Recruitment of OPs to the demyelinating lesions is critical for the induction of remyelination, which requires their proliferation followed by recruitment and differentiation into myelinating mature oligodendrocytes (11, 12 ).”
BackgroundCarson, M. J., Behringer, R. R., Brinster, R. L., & McMorris, F. A. (1993) · Neuron · doi:10.1016/0896-6273(93)90173-o · Cited by 474
Pro‐regenerative properties of cytokine‐activated astrocytes
Liberto, C. M., Albrecht, P. J., Herx, L. M., Yong, V. W., & Levison, S. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02420.x · Cited by 464
Liang, X., Draghi, N. A., & Resh, M. D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5319-03.2004 · Cited by 255
Jurevics, H., Hostettler, J., Muse, E. D., Sammond, D. W., Matsushima, G. K., Toews, A. D., & Morell, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00310.x · Cited by 53 · cited 1×
“Likewise, the increase in biosynthesis of both cerebrosides and galactolipids is considered to be an important determinant of myelin development, remyelination, and axo-glial organization in various CNS demyelination models (30, 31).”
Background
Cited by
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism
Poitelon, Y., Kopec, A. M., & Belin, S. (2020) · Cells · doi:10.3390/cells9040812 · Cited by 394
“These principles may be translated into therapeutic opportunities for neuropathies either associated with myelin deficits or extended to disorders associated with white matter defects [171,172].”
BackgroundLipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models
Chrast, R., Saher, G., Nave, K.-A., & Verheijen, M. H. G. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009761 · Cited by 314
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
“In addition, Paintlia et al., 2005 reported that statins improve proliferation and survival of oligodendrocyte precursors in vitro and improve myelination in vivo, also via a GGPP-dependent mechanism.”
Cholesterol: A Novel Regulatory Role in Myelin Formation
Saher, G., Quintes, S., & Nave, K.-A. (2011) · The Neuroscientist · doi:10.1177/1073858410373835 · Cited by 144
Metadata
- Authors
- Paintlia, A. S., Paintlia, M. K., Khan, M., Vollmer, T., Singh, A. K., & Singh, I.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 19
- Issue
- 11
- Pages
- 1407-1421
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2145859941
- Cited by
- 107
- References
- 8
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. https://app.cochat.ai/papers/10.1096/fj.05-3861com
- The paper
- Paintlia, A. S., Paintlia, M. K., Khan, M., Vollmer, T., Singh, A. K., & Singh, I. (2005). HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. The FASEB Journal. https://doi.org/10.1096/fj.05-3861com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.